N-SUBSTITUTED DIOXOCYCLOBUTENYLAMINO-3-HYDROXYPICOLINAMIDES SUITABLE AS CCR6 INHIBITORS Russian patent published in 2022 - IPC C07D401/12 C07D401/14 C07D405/14 C07D413/12 C07D413/14 C07D417/12 A61K31/4439 A61P37/00 A61P29/00 

FIELD: organic chemistry.

SUBSTANCE: invention relates to the field of organic chemistry, namely to compounds of N-substituted dioxocyclobutenylamino-3-hydroxypicolinamide of formulas (IA and IB) or its pharmaceutically acceptable salts, where R₁ and R₂ are independently (C₁-C₆)alkyl, or R₁ and R₂, taken together with a nitrogen atom, to which they are attached, form 6-element heterocycle containing one N heteroatom and 1 additional heteroatom selected from a group consisting of O and N, where heterocycle is optionally substituted with one (C₁-C₄)alkyl group; R₃ is H; A is R₄ is (C₁-C₄)alkyl; R₅ and R₆ are independently H, (C₁-C₄)alkoxy, (C₁-C₄)alkyl, (C₁-C₄)alkyl-d_1-9, (C₃-C₄)cycloalkyl, cyano, halogen atom, halogen(C₁-C₄)alkoxy, or hydroxy(C₁-C₄)alkyl; B is R₇ is (C₁-C₃)alkyl; R₈, in each case, is independently deuterium, or two R₈ attached to the same carbon atom form (C₃-C₅)cycloalkyl group; n is equal to 0 or 2; R₉, in each case, is independently deuterium or -F; m is equal to 2; and X is O. The invention also relates to specific compounds of N-substituted dioxocyclobutenylamino-3-hydroxypicolinamide of formulas (IA and IB).

EFFECT: compounds are obtained, which inhibit CC-chemokine receptor 6 (hereinafter – CCR6), useful in the treatment or prevention of conditions or diseases weakened by CCR6 inhibition.

13 cl, 12 dwg, 17 tbl, 42 ex